Company: ENTXW
Filing Date: 2025-06-05
Form Type: DEF 14A
Source: 0001178913-25-002111
Chunk: 64

Company: Entera Bio Ltd.
Filing Date: 2025-06-05
Form: DEF 14A
Chunk 64
---
 a similar size to the Company. The Compensation Committee and Board have further determined that it would be in the best interests of the Company to update and amend the Company’s compensation policy, as outlined in Proposal Five below. Had the updated compensation policy, to be approved per Proposal Five below, been in effect as of the date hereof, the revised compensation terms below would be considered materially consistent with our compensation policy and would thereby not require shareholder approval. A significant portion of the Chief of Research & Development’s total compensation is “at-risk” in the form of equity compensation and is directly tied to the Company’s share performance. As a result, this component of compensation aligns the Chief of Research & Development’s interests with those of shareholders by linking potential rewards to long-term stock price appreciation. Pursuant to the Israeli Companies Law, any transaction between us and an office holder (as defined in the Companies Law), relating to his or her terms of compensation, must generally be consistent with our compensation policy, and must be approved by the Compensation Committee, the Board and a Special Majority of our shareholders, to the extent applicable, in accordance with the provisions of the Israeli Companies Law. Terms of Revised Compensation The terms of the revised compensation to Dr. Burshtein, effective as of the approval of our shareholders at this Annual Meeting, would be as follows:

| (i) | 2025 Option Grant. Dr. Burshtein will be entitled to receive an additional one-time grant of options to purchase an additional200,000 Ordinary Shares (the “2025                                                                               
 Options”), at an exercise price of $2.28 per Ordinary Share, under the 2018 Plan, and subject to the requirements of applicable laws and regulations. The 2025 Options shall vest as follows: provided that Dr. Burshtein has not undergone a  
 Termination of Service (as defined in the 2018 Plan) prior to the applicable vesting date, the 2025 Options shall vest over a three (3) year period, with a third of the 2025 Options vesting at the end of a 12-month period following April  
 28, 2025, and the remaining two-thirds of the 2025 Options shall vest in eight substantially equal portions over the next two (2) year period thereafter, on a quarterly basis, rounded down to the nearest whole share, provided, that with   
 respect to the last such quarterly installment, the number of 2025 Options that vest in the installment shall be such that Dr.